Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 3 of 195
Pharmaceutical Business review is using cookies

ContinueLearn More

All articles by vbandhakavi 

FDA committee recommends BMS-2seventy’s Abecma

Abecma is a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell immunotherapy. The ODAC validated the favourable benefit/risk profile of the therapy based on findings from the Phase